FOR US HEALTHCARE PROFESSIONALS ONLY

Open-label extension study

Long-term safety and efficacy are being evaluated in an ongoing extension study1,*

The open-label extension study includes prior clinical trial participants and treatment-naive patients (N=194).

Treated and screened patients from prior trials

Group 1

Continued on DUVYZAT
(n=110)

Previously treated with DUVYZAT + corticosteroids in a phase 2 clinical trial or EPIDYS

Group 2

Switched from placebo
(n=54)

Previously treated with placebo + corticosteroids in EPIDYS

Group 3

Newly enrolled
(n=30)

Screened for prior trials but not enrolled; started on DUVYZAT in open-label extension

Open-label extension study

Received DUVYZAT + corticosteroids (N=194)

Mean duration >18 months

Baseline characteristics and patient demographics in the open-label extension study were consistent with EPIDYS.

Open-label extension study objectives:

Primary objective:

  • To evaluate the long-term safety and tolerability of DUVYZAT in patients with DMD

Key secondary endpoints:

  • Change from baseline at end of each year in:
    • Timed function tests (TTRF, 10MWT)
    • Motor function and muscle strength as assessed by NSAA
    • 6-minute walk test
    • Knee extension and elbow flexion

Post hoc analysis:

  • Efficacy endpoints evaluated patients taking DUVYZAT against natural history cohorts that were propensity score matched for age, disease stage, and corticosteroid usage (CINRG DNHS and ImagingDMD)

PRIMARY ENDPOINT: SAFETY

Long-term safety of DUVYZAT remained consistent with EPIDYS1

Adverse events in the open-label extension

Received givinostat throughout (n=110) Received placebo in prior study (n=54) Not included in prior study (n=30)
Adverse event, n (%) 96 (87.3) 47 (87.0) 26 (86.7)
Hypertrigly­ceridemia 23 (20.9) 11 (20.4) 2 (6.7)
Fall 22 (20.0) 5 (9.3) 4 (13.3)
Diarrhea 20 (18.2) 15 (27.8) 11 (36.7)
Thrombo­cytopenia§ 19 (17.3) 19 (35.2) 5 (16.7)
Pyrexia 19 (17.3) 7 (13.0) 2 (6.7)
Headache 16 (14.5) 9 (16.7) 6 (20.0)
Vomiting 16 (14.5) 8 (14.8) 5 (16.7)
Abdominal pain 12 (10.9) 9 (16.7) 1 (3.3)
Adverse event considered related to treatment, n (%) 60 (54.5) 36 (66.7) 18 (60.0)
Hypertrigly­ceridemia 21 (19.1) 10 (18.5) 2 (6.7)
Thrombo­cytopenia§ 19 (17.3) 18 (33.3) 5 (16.7)
Diarrhea 10 (9.1) 9 (16.7) 10 (33.3)
Abdominal pain 5 (4.5) 5 (9.3) 1 (3.3)
Serious adverse event, n (%) 12 (10.9) 8 (14.8) 3 (10.0)
Femur fracture 3 (2.7) 3 (5.6) 0
Tendinous contracture 2 (1.8) 0 0
Back pain 1 (0.9) 1 (1.9) 0
Dehydration 1 (0.9) 1 (1.9) 0
Serious adverse event considered related to treatment, n (%) 0 1 (1.9) 0
Life-threatening or fatal
adverse event, n (%)
0 0 0
Adverse event leading to study treatment discontinu­ation, n (%) 1 (0.9) 2 (3.7) 0
Adverse event leading to study withdrawal, n (%) 1 (0.9) 2 (3.7) 0

Includes blood triglycerides increased or hypertriglyceridemia.

§ Includes platelet count decreased or thrombocytopenia.

DUVYZAT safety results consistent with findings from EPIDYS.

  • Most patients (169/194) experienced ≥1 adverse event
    • Serious adverse events occurred in 23/169 patients and included femur fracture (n=6), tendinous contracture (n=2), back pain (n=2), and dehydration (n=2)
    • Severe events occurred in 21/169 patients and included femur fracture (n=4), back pain (n=3), and hypertriglyceridemia (n=2)
  • No fatal or life-threatening events
  • The most common treatment-related adverse events (hypertriglyceridemia, thrombocytopenia, and diarrhea) typically occurred within the first few weeks of treatment and were manageable with dose modification
  • In the open-label extension, patients previously treated with DUVYZAT experienced a lower incidence of diarrhea compared with those newly initiating treatment
  • Patients in the open-label extension remained on DUVYZAT for a mean duration >18 months

SECONDARY ENDPOINTS

In the secondary endpoints, baseline function declined and disease progression continued as expected in all 3 groups1

No patients in the open-label extension study received placebo, therefore disease progression was not measured against a comparator.

POST HOC ANALYSIS

Long-term data demonstrate how DUVYZAT helps PROTECT against DMD progression1,∥

DUVYZAT + corticosteroids delayed loss of ambulation compared to natural history cohorts taking corticosteroids

Age at persistent loss of ambulation

NOTE: Patients who did not reach a disease milestone or those who were lost to follow-up were censored on the last date they were known to be in the study.2

DUVYZAT + corticosteroids delayed loss of 4SC ability compared to natural history cohorts taking corticosteroids

Age at persistent loss of 4SC ability

NOTE: Patients who did not reach a disease milestone or those who were lost to follow-up were censored on the last date they were known to be in the study.2

DUVYZAT + corticosteroids delayed loss of ability to rise from the floor compared to natural history cohorts taking corticosteroids

Age at persistent loss of ability to rise from the floor

NOTE: Patients who did not reach a disease milestone or those who were lost to follow-up were censored on the last date they were known to be in the study.2

4SC, 4-stair climb.

As measured by the median difference between DUVYZAT and natural history cohorts. Comparisons were conducted using propensity score–matching methodology. Natural history data were obtained prospectively from multicenter studies (CINRG DNHS and ImagingDMD) and matched to key EPIDYS inclusion criteria.1

Explore the efficacy and safety results from the phase 3 trial.

References: 1. McDonald CM, Guglieri M, Vučinić D, et al. Long-term evaluation of givinostat in Duchenne muscular dystrophy, and natural history comparisons. Ann Clin Transl Neurol. 2025;12(11):2335-2348. 2. Gomez Andres D, Sansone VA, Phan HC, et al. Givinostat efficacy in Duchenne muscular dystrophy: natural history comparison applying propensity score matching. Poster presented at: Muscular Dystrophy Association Clinical & Scientific Conference; March 16-19, 2025; Dallas, TX.

More than 2000 people with DMD have been prescribed DUVYZAT.2,† Includes global patients (US and EU participants).

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Hematological Changes: DUVYZAT can cause dose-related thrombocytopenia and other signs of myelosuppression. Monitor blood count every 2 weeks for the first 2 months, at month 3, and every 3 months thereafter. Modify the dosage for confirmed thrombocytopenia. Discontinuation may be needed if abnormalities worsen.
  • Increased Triglycerides: DUVYZAT can cause elevations in triglycerides. Monitor triglycerides at 1 month, 3 months, 6 months, and then every 6 months thereafter. Modify the dosage if fasting triglycerides are verified >300 mg/dL. Treatment with DUVYZAT should be discontinued if triglycerides remain elevated despite adequate dietary intervention and dosage adjustment.
  • Gastrointestinal Disturbances: Gastrointestinal disturbances, including diarrhea, nausea/vomiting, and abdominal pain were common adverse reactions in DUVYZAT clinical trials. Antiemetics or antidiarrheal medications may be considered during treatment with DUVYZAT. Modify the dosage of DUVYZAT in patients with moderate or severe diarrhea and discontinue treatment if significant symptoms persist.
  • QTc Prolongation: DUVYZAT can cause prolongation of the QTc interval. Avoid use of DUVYZAT in patients who are at an increased risk for ventricular arrhythmias (including torsades de pointes), such as those with congenital long QT syndrome, coronary artery disease, electrolyte disturbance or in patients taking concomitant medicinal products known to cause QT prolongation. Obtain ECGs prior to initiating treatment with DUVYZAT in patients with underlying cardiac disease or in patients who are taking concomitant medications that cause QT prolongation.

Adverse Reactions

The most common adverse reactions reported in >5% of patients treated with DUVYZAT are diarrhea (37%), abdominal pain (34%), thrombocytopenia (33%), nausea/vomiting (32%), hypertriglyceridemia (23%), pyrexia (13%), myalgia (9%), rash (9%), arthralgia (8%), fatigue (8%), constipation (7%), and decreased appetite (7%).

Drug Interactions

Closely monitor when DUVYZAT is used in combination with an oral CYP3A4 sensitive substrate or a sensitive substrate of the OCT2 transporter, for which a small change in substrate plasma concentrations may lead to serious toxicities.

Avoid concomitant use with other drugs that prolong the QTc interval; monitor ECG if concomitant use cannot be avoided. If concomitant use cannot be avoided, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold DUVYZAT if the QTc interval is >500 ms or the change from baseline is >60 ms.

INDICATION

DUVYZAT is a histone deacetylase inhibitor indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.

To report SUSPECTED ADVERSE REACTIONS, contact ITF Therapeutics LLC at 1-833-582-4312 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for additional safety information.

More than 2000 people with DMD have been prescribed DUVYZAT.2,† Includes global patients (US and EU participants).

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Hematological Changes: DUVYZAT can cause dose-related thrombocytopenia and other signs of myelosuppression. Monitor blood count every 2 weeks for the first 2 months, at month 3, and every 3 months thereafter. Modify the dosage for confirmed thrombocytopenia. Discontinuation may be needed if abnormalities worsen.
  • Increased Triglycerides: DUVYZAT can cause elevations in triglycerides. Monitor triglycerides at 1 month, 3 months, 6 months, and then every 6 months thereafter. Modify the dosage if fasting triglycerides are verified >300 mg/dL. Treatment with DUVYZAT should be discontinued if triglycerides remain elevated despite adequate dietary intervention and dosage adjustment.
  • Gastrointestinal Disturbances: Gastrointestinal disturbances, including diarrhea, nausea/vomiting, and abdominal pain were common adverse reactions in DUVYZAT clinical trials. Antiemetics or antidiarrheal medications may be considered during treatment with DUVYZAT. Modify the dosage of DUVYZAT in patients with moderate or severe diarrhea and discontinue treatment if significant symptoms persist.
  • QTc Prolongation: DUVYZAT can cause prolongation of the QTc interval. Avoid use of DUVYZAT in patients who are at an increased risk for ventricular arrhythmias (including torsades de pointes), such as those with congenital long QT syndrome, coronary artery disease, electrolyte disturbance or in patients taking concomitant medicinal products known to cause QT prolongation. Obtain ECGs prior to initiating treatment with DUVYZAT in patients with underlying cardiac disease or in patients who are taking concomitant medications that cause QT prolongation.

Adverse Reactions

The most common adverse reactions reported in >5% of patients treated with DUVYZAT are diarrhea (37%), abdominal pain (34%), thrombocytopenia (33%), nausea/vomiting (32%), hypertriglyceridemia (23%), pyrexia (13%), myalgia (9%), rash (9%), arthralgia (8%), fatigue (8%), constipation (7%), and decreased appetite (7%).

Drug Interactions

Closely monitor when DUVYZAT is used in combination with an oral CYP3A4 sensitive substrate or a sensitive substrate of the OCT2 transporter, for which a small change in substrate plasma concentrations may lead to serious toxicities.

Avoid concomitant use with other drugs that prolong the QTc interval; monitor ECG if concomitant use cannot be avoided. If concomitant use cannot be avoided, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold DUVYZAT if the QTc interval is >500 ms or the change from baseline is >60 ms.

INDICATION

DUVYZAT is a histone deacetylase inhibitor indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.

To report SUSPECTED ADVERSE REACTIONS, contact ITF Therapeutics LLC at 1-833-582-4312 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for additional safety information.